LEVIMMUNE Trademark

Trademark Overview


On Wednesday, January 8, 2020, a trademark application was filed for LEVIMMUNE with the United States Patent and Trademark Office. The USPTO has given the LEVIMMUNE trademark a serial number of 88751609. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 7, 2022. This trademark is owned by CytoDyn Inc.. The LEVIMMUNE trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor

Providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and dis...

Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor
levimmune

General Information


Serial Number88751609
Word MarkLEVIMMUNE
Filing DateWednesday, January 8, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 7, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 9, 2020

Trademark Statements


Goods and ServicesTherapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor
Goods and ServicesProviding health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
Goods and ServicesScientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 13, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 13, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 13, 2020
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCytoDyn Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressVancouver, WA 98660

Party NameCytoDyn Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressVancouver, WA 98660

Trademark Events


Event DateEvent Description
Monday, March 7, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 7, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, July 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 13, 2021SOU EXTENSION 2 GRANTED
Tuesday, July 13, 2021SOU EXTENSION 2 FILED
Tuesday, July 13, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, January 12, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 8, 2021SOU EXTENSION 1 GRANTED
Friday, January 8, 2021SOU EXTENSION 1 FILED
Friday, January 8, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, August 4, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 9, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 9, 2020PUBLISHED FOR OPPOSITION
Wednesday, May 20, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, May 4, 2020ASSIGNED TO LIE
Friday, April 24, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, April 24, 2020EXAMINER'S AMENDMENT ENTERED
Friday, April 24, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, April 24, 2020EXAMINERS AMENDMENT E-MAILED
Friday, April 24, 2020EXAMINERS AMENDMENT -WRITTEN
Wednesday, April 22, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 21, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 21, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, March 28, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, March 28, 2020NON-FINAL ACTION E-MAILED
Saturday, March 28, 2020NON-FINAL ACTION WRITTEN
Thursday, March 26, 2020ASSIGNED TO EXAMINER
Monday, January 13, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, January 11, 2020NEW APPLICATION ENTERED